NEWS: "Hot Off the Press"
- 2025 Virtual Tech Conference
- Alpha Modus Expands Strategic Patent Licensing Program with VSBLTY Partnership
- ZenaTech’s ZenaDrone to File Patent and Accelerate Deployment of Counter-UAS Technology on the ZenaDrone 1000 in Response to US Executive Order
- Alpha Modus Ventures Files Patent Infringement Lawsuit Against Cisco Systems
- Historic Executive Order Fast-Tracks ZenaTech’s ZenaDrone Subsidiary Manufacturing and Go-to-Market Plans for Dual-Use Defense and Commercial Drones
- Investor Presentation Recorded On Apr 24th 2025
- ZenaTech Launches Drone as a Service (DaaS) for US Defense and Government Agencies with New Partnerships
- Alpha Modus Appoints Tim Matthews as Head of Deployment Strategy to Accelerate CashX Rollout
- ZenaTech Pushes Forward on AI Drone Swarms, US Military Applications, and Quantum Computing Initiatives to be Highlighted at Three Upcoming Investor Conferences
- ZenaTech Developing Quantum Computing and AI Drone Fleets to Prevent Wildfires in the Western US
- RMX (Reticulate Micro) Secures GSA Schedule Placement, Enhancing Government Market Access
- IQSTD - IQSTEL Reports Strong Preliminary Q1 2025 Results: Revenue Growth, Margin Expansion, and Strategic Progress Toward NASDAQ Uplisting
- Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma
- Reticulate Micro’s VAST Platform to Power Advanced Tactical Video at SOF Week 2025
- Beverage Brands Are Moving From Flavor to Function and It's Paying Off for Investors
- IQSTEL Announces Strategic Decision to Uplist to NASDAQ and Executes Reverse Stock Split to Meet Minimum Listing Requirements
- iQSTEL Announces Reverse Stock Split in Preparation for Uplist to Nasdaq
- Top Penny Stocks To Watch In May 2025
- NIP Group Inc (NIPG) (Q4 2024) Earnings Call Highlights: Navigating Growth and Challenges in a ...
- Full Year 2024 NIP Group Inc Earnings Call
- Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting
- NIP Group Inc. Reports Second Half and Full Year 2024 Unaudited Financial Results
- Cycurion, Inc. Announces $6 Million Contract Award by Major Municipal Transportation Agency
- Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting
- Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma
- NIP Group to Report Unaudited Financial Results for the Second Half and Full Year 2024 on April 30, 2025
- Forget Sugary Sodas Wellness Drinks Are Gaining Ground With Consumers and Investors
- Ascent Solar Technologies Hosts Customer and Partner Discussions During Space Symposium
- Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting
- Reticulate Micro, Inc. Completes Acquisition of Remaining RMX Industries Inc. Shares, Consolidates Operations, and Expands Leadership Team
- Green Leaf Innovations Announces Q1 Corporate Update and Board Resolution
- Northann Corp. Receives NYSE Notice Regarding Late Filing of Annual Report on Form 10-K
- Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs
- Opus Holdings Unveils Powerhouse Leadership Team to Drive Aggressive Growth and Transform Market Trajectory
- Cycurion, Inc. Announces Expansion into Latin America Through Partnership with LSV-TECH International of Colombia
- Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings
- Safety Shot, Inc. Postpones Record Date for Spin-Off and Distribution of Shares Common Stock of Caring Brands, Inc. - Updated
- Cycurion Reports Full Year 2024 Financial Results
- Green Leaf Innovations Reports Exponential Revenue Growth for 2024
- VSee Unveils Advanced Telenursing Robotics Solution Targeting 3-5% Reduction in Hospital Nursing Costs
